|Bid||16.59 x 900|
|Ask||16.61 x 1400|
|Day's Range||15.79 - 16.97|
|52 Week Range||4.14 - 26.02|
|Beta (3Y Monthly)||2.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 5, 2020 - Feb 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.17|
Anyone researching Myovant Sciences Ltd. (NYSE:MYOV) might want to consider the historical volatility of the share...
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Myovant Sciences (MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that Lynn Seely, M.D., Myovant’s President and CEO, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Tuesday, December 3, 2019 at 10:35 a.m. Eastern Time in Boston, MA. A live webcast of the presentation will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com. Myovant Sciences aspires to be the leading healthcare company focused on innovative treatments for women’s health and prostate cancer.
One of the biggest things I’ve tried to stress in my training for this upcoming small account challenge, both to myself and to my students, is that my daily profits are not going to be as mind-bogglingly ...
Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.
Myovant Sciences also will seek FDA approval next year of a different version of the same drug to treat heavy menstrual bleeding in women with uterine fibroids.
Myovant Sciences Ltd. shares soared 79% in premarket trade Tuesday, after the healthcare company said a late-stage trial of a treatment for advanced prostate cancer achieved a 97% response rate. Basel, Switzerland-based Myovant said its phase 3 trial dubbed Hero of oral relugolix met its primary endpoint as well as all six key secondary endpoints. The company is planning to submit a new drug application to the U.S. Food and Drug Administration in the second quarter of 2020 and will pursue regulatory approvals in Europe and Japan. In the analysis of the primary endpoint, 97% of men receiving the drug once daily achieved sustained testosterone suppression, the company said. Shares have fallen 63.0% in 2019 through Monday, while the S&P 500 has gained 24.5%.
Shares of thinly-traded, small-cap biotech Myovant Sciences Ltd (NYSE: MYOV ) are skyrocketing Tuesday, the catalyst being a positive late-stage clinical readout . What Myovant Said About Relugolix Myovant ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
Myovant Sciences (MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that the Phase 3 HERO study of once-daily, oral relugolix (120 mg) met its primary efficacy endpoint and all six key secondary endpoints in men with advanced prostate cancer. “An oral gonadotropin-releasing hormone, or GnRH, antagonist for advanced prostate cancer has been an aspiration for many years,” said Neal Shore, M.D., Medical Director of the Carolina Urologic Research Center and HERO Program Steering Committee Member.
BASEL, Switzerland, Nov. 18, 2019 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer,.
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women’s health and prostate cancer, today announced recent corporate updates and reported financial results for the second fiscal quarter ended September 30, 2019. “Myovant continues to make great progress towards our milestones and is poised for a strong commercial launch of relugolix if approved, with two positive Phase 3 studies evaluating relugolix combination therapy in women with uterine fibroids and approximately $500 million in total cash and committed financing, including the Sumitomo Dainippon Pharma term loan facility,” said Lynn Seely, M.D., President and CEO of Myovant Sciences.
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]
The S&P 500 closed at an all time high on Monday evening -- then closed at an even higher high on Wednesday -- 3,046.77. Goldman Sachs believes this rally could keep going well into 2020.A recent report from Goldman Sachs predicts that 2020 will see corporations spend nearly a half-trillion dollars on stock buybacks, mergers, and acquisitions next year. Add in buying by U.S. individual investors and foreign investors, and that buying could be pushed well beyond the $500 billion-mark, says Goldman Sachs analyst David Kostin, as investors seek to profit from "positive equity market returns," buoyed by "rising interest rates, and stabilizing US and World GDP growth."But where do you look to find those profits specifically?Using the Stock Screener at TipRanks to seek out highly rated stocks in the ever-growing healthcare sector, for which Goldman Sachs analysts expect to see double, near double, or more than double returns in the next 12 months, we've come up with three candidates for you today.Arvinas Holding (ARVN)Based in New Haven, Connecticut, cancer-fighter Arvinas is researching therapies to degrade cancer-causing proteins in diseases such as prostate cancer and breast cancer.Goldman Sachs analyst Terence Flynn upgraded Arvinas to "buy" with a $38 price target after reviewing the result of Phase 1 clinical trials of the company's ARV-110 (for prostate cancer) and ARV-471 (for breast cancer) drugs. (To watch Flynn's track record, click here)As the label "Phase 1" suggests, Flynn admits that "trials are still in the early stages," but initial safety data looks good, opening a path to proceed to evaluating "first clinical efficacy data." Flynn increases his probability of success for both ARV-110 and ARV-471 to 25% (vs. 20% prior) given the initial safety/PK data presented, which in his view "provide some incremental de-risking of the drugs."If all goes well, Flynn foresees "blockbuster potential" for both drugs, with potential peak sales of $2.9 billion and $4.7 billion, respectively -- a big improvement over the $15 million in revenue Arvinas has booked over the last 12 months.Street sentiment on this one is good as well, with three analysts initiating coverage of Arvinas over the last three months -- in addition to Goldman's upgrade. And like Goldman, all three of these other analysts rate the stock a "buy," which qualifies the stock for "strong buy" sentiment in our book. A consensus target price of $38 (in line with Goldman's own target price) implies 81% upside for the shares over the next 12 months. (See Arvinas stock analysis on TipRanks)Livongo Health (LVGO)Next up: taking a different path to healthcare, Livongo Health is a Mountain View, California, software company seeking to harness data to improve patient outcomes in the fields of hypertension treatment, diabetes care, and weight management.This one attracted the attention of Goldman Sachs analyst Robert Jones, after Livongo was awarded a contract "to provide the Livongo for Diabetes solution to eligible members covered by the Federal Employees Health Benefits program under one health plan covering 5.3mn lives." Beginning on January 1, 2020, and for at least nine to 12 months thereafter, Livongo will work to reduce diabetes in the federal workforce -- and receive between $20 million and $25 million for its services in 2020, and perhaps $30 million to $35 million in 2021 if all goes well.This single contract, therefore, holds the potential to grow Livongo's $113 million in trailing revenues by 22% next year -- and push Livongo stock up as high as $43 a share, in Jones' estimation, over the next 12 months.The rest of Wall Street is even more optimistic. More than half a dozen analysts have chimed in over the past couple of months, most with buy ratings, and with an average price target of $43.63. If they're right, that means Livongo stock could more than double over the next 12 months. (See Livongo stock analysis on TipRanks)Myovant Sciences (MYOV) Returning to the pharmaceutical field now, but shifting our gaze to the UK, London-based Myovant Sciences is a clinical-stage biopharmaceutical company working to develop drugs for use in women's health, with backing from Japan's Sumitomo Dainippon Pharma, which took a 46% stake in the company last quarter and is helping to move Myovant towards commercial production.Goldman Sachs analyst Paul Choi isn't looking for earnings to be much of a catalyst for the stock (because there are none). But sales revenue is anticipated to begin rolling in next year, and could quadruple to more than $153 million by 2021. Furthermore, Choi recommends the stock in anticipation of the companies signing a "definitive agreement" of their partnership, assigning Myovant stock a "buy" rating and an $18 price target. (To watch Choi's track record, click here)Wall Street as a whole is similarly bullish, with three "buy" ratings filed in the last two months (including Goldman's), making the stock a "Strong Buy" according to TipRanks. With Street analysts positing an average $22 average price target, Myovant shows the most profit potential of all on today's list -- 325% to be exact. (See Myovant stock analysis on TipRanks)
BRISBANE, Calif. and BASEL, Switzerland, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that it has entered into a landmark agreement with Sumitomo Dainippon Pharma Co., Ltd. (TSE:4506), a leading Japanese pharmaceutical company, on a $350 million low-interest, five-year term loan facility and an Investor Rights Agreement. This agreement was made in conjunction with Myovant’s founding shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma entering into a definitive agreement for the creation of a broad strategic alliance.
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that it has completed patient recruitment for its SPIRIT 1 study, the second of two Phase 3 replicate studies evaluating relugolix combination therapy in women with endometriosis-associated pain. “The completion of recruitment for the SPIRIT program marks another important step in achieving our goal to bring a best-in-class, non-invasive treatment option to women suffering from endometriosis, that has predictable efficacy and tolerability and is potentially suitable for long-term use,” said Juan Camilo Arjona Ferreira, M.D., Chief Medical Officer of Myovant Sciences.
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
Pervasive stigma and prevalent symptoms related to menstruation are among the key takeaways from a new survey conducted by Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and Evidation Health, a health and measurement company that helps life sciences companies understand how everyday behavior and health interact.
Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, announced today the formation of Female Forward Together, a cross-sector coalition bringing together expertise in healthcare, research, data science, digital health, and advocacy to improve women’s health.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
BRISBANE, Calif., and BASEL, Switzerland, Oct. 10, 2019 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health.